Big Pharma Spin-Offs are in Favor, says MPM's Michael Steinmetz

Dismal markets mean good opportunities for investors, says Michael Steinmetz, PhD, general partner at MPM Capital. But their preference for putting larger sums into more mature companies make Big Pharma spin-offs particularly attractive-especially in Europe.